作者: R.L. Theriault , R.V. Sellin
DOI: 10.1093/OXFORDJOURNALS.ANNONC.A057847
关键词:
摘要: Summary It is common practice to forego the prescribing of estrogen replacement therapy (ERT) for patients with a history breast cancer. The consequences deprivation particularly cardiovascular morbidity and osteoporosis are reviewed in context potential risks ERT prior published data regarding cancer oral contraceptive use healthy women reviewed. rationale clinical trial patients, proposed appropriate patient group positive end points assessing benefit population presented. Lack reliable makes an unresolved dilemma.